Reports form Hain Celestial Group, Fabrinet, Vertex Pharmaceuticals and Apple

After the market close, Hain Celestial Group (HEIN) announced the delay of its fourth quarter and fiscal 2016 results, which led to a 25% dive. The organic and natural products company said in a statement that it identified concessions granted to certain U.S. distributors during the fourth quarter and is evaluating whether the revenue associated with those concessions was accounted for in the correct period.

Fabrinet (FN) gained more than 5 percent following the company's fourth-quarter and fiscal-year 2016 results. Fourth-quarter revenue was $276.4 million, a 34 percent increase from total revenue of $206.5 million in the prior-year period. The optical packaging and electronic manufacturer increased revenue by 26 percent for fiscal year 2016 to $979.7 million from $773.6 million for the prior year. The company expects first-quarter revenue to be in the range of $306 million to $310 million.

Vertex Pharmaceuticals (VRTX) fell more than 3 percent after the company announced the discontinuation of the Phase 3 program for its lead pipeline drug, VX-661. The study revolves around the treatment of cystic fibrosis patients. Vertex said in a statement that it plans to submit a New Drug Application to the FDA for VX-661 in the second half of 2017.

Apple (APPLE) edged slightly higher after hours following Warren Buffett's Berkshire Hathaway saying in a filing that it increased its stake. Berkshire boosted its share stake by about 55 percent to 15.2 million shares as of June 30.

Read more:

• US – Iran – Iraq tension remain the main driver of the stock market today
• How top market players on Wall St think 2020 will look like on financial markets
• Money Flow before the start of the new trading week
• Cincinnati Financial Corporation (CINF.US) -Opportunity for long positions
• Asia stocks gain as Fed signals no rate cuts in 2020